sglt2 vs glp 1 vs dpp4 Inhibitors GLP-1 Agonists | June 2021 | Clinical Corner SGLT2 inhibitor versus DPP-4 inhibitor

Jul 16, 2026 FDA Publishes All 7 Briefing Documents Ahead of the July 2026 PCAC Meeting The FDA has posted all seven scientific briefing documents for the July 2324, 2026 Pharmacy Compounding Advisory Committee meeting an unusually clear window into the agency's current thinking on peptide safety, efficacy, and characterization

The paper cites estimates that purchasers (including insurers and patients) may be paying as much as 20 percent more than the cash price of a given generic drug because of practices by PBMs and other intermediaries such as wholesalers

The trial data show that stopping often leads to regain, which is why the decision should be made with your provider based on your goals and health (STEP 1 extension, PMC)

Elrick et al